Effects of Risk Presentation Format and Frequently Asked Questions on Breast Cancer Risk Skepticism

ConditionBreast Cancer
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age39-74
SponsorUniversity of Colorado, Denver

About this trial

The purpose of this study is to find out whether the way a breast cancer risk estimate is presented affects how women feel about their risk and whether they believe the estimate is accurate for them. Women aged 39-74 will complete an online survey in which they receive a personalized breast cancer risk estimate using the Breast Cancer Risk Assessment Tool (BCRAT). The study includes two experiments. In the first experiment, women are randomly assigned to receive their estimate in different formats: some will see their risk over 5 years, 10 years, or a lifetime, and some will see their risk expressed out of 100 women or out of 1,000 women. In the second experiment, women receive their estimate and then have the opportunity to read answers to frequently asked questions about how breast cancer risk is calculated and what the estimate means. In both experiments, women are asked whether they believe the estimate reflects their true risk. Both experiments are conducted online through a national survey panel.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Female sex

Age 39-74 (i.e., people who are eligible for routine breast cancer screening and for whom guidelines recommend an informed, risk-based decision)

English literacy

Disqualifiers

breast cancer

Ductal carcinoma in situ (DCIS)

Lobular carcinoma in situ (LCIS)

Known BRCA1/2 gene mutation

Trial design

Design model

Factorial

Treatments tested in this trial

  • Risk Presentation Format

    Behavioral

    Participants receive a personalized breast cancer risk estimate generated by the Gail Model. The format of the estimate varies by random assignment across two dimensions: temporal framing (5-year, 10-year, or lifetime risk) and denominator (risk expressed out of 100 women or out of 1,000 women). All other elements of the risk presentation are held constant across conditions.

  • Frequently Asked Questions Exposure

    Behavioral

    Participants receive a personalized breast cancer risk estimate generated by the Gail Model and then view an interactive FAQ document. The FAQ document was developed from qualitative interviews with women who had previously rejected their risk estimates and addresses common questions about how breast cancer risk is calculated, what factors the model does and does not include, what different risk levels mean, and how to discuss results with a physician. FAQ items are displayed as expandable questions; participants click to reveal answers. All participants receive the same FAQ document.

Treatment groups

3,000 Participants
are divided into 6 treatment groups

6

Treatment groups

See each treatment group below.

Group A: 5 Year Risk AND N-in-100 PresentationExperimental treatment 2 interventions
Group B: 10 Year Risk AND N-in-100 PresentationExperimental treatment 2 interventions
Group C: Lifetime Risk AND N-in-100 PresentationExperimental treatment 2 interventions
Group D: 5 Year Risk AND N-in-1000 PresentationExperimental treatment 2 interventions
Group E: 10 Year Risk AND N-in-1000 PresentationExperimental treatment 2 interventions
Group F: Lifetime Risk AND N-in-1000 PresentationExperimental treatment 2 interventions

Trial outcomes

Primary outcomes

1

Risk Skepticism

Participants' perception of their Gail model risk estimate is trichotomized into three categories: Underestimator (believed risk is lower than estimate), Agreer (believed risk equals estimate), and Overestimator (believed risk is higher than estimate).

Time frame
Day 1
2

Risk Perception

This measure includes two Likert scale questions assessing the perceived likelihood of developing cancer and the level of worry about getting cancer.

Time frame
Day 1

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of Colorado, Denver

Lead sponsor

National Cancer Institute (NCI)

Collaborator

This trial is not recruiting at the moment. You can still explore other options: